3 Houston innovators to know this week

who's who

This week's Houston innovators to know are Megan Eddings, Lance Black, and Todd Burke.

The city of Houston — much like most major cities in the country — is in crisis mode, with a stay-at-home mandate and rising COVID-19 case numbers.

But these three Houston innovators are emerging as leaders in making masks, discussing the importance of telemedicine at this time, and providing tips on keeping a stable supply chain.

Megan Eddings, founder of Accel Lifestyle

Photo courtesy of Accel Lifestyle

Former scientist Megan Eddings designed a fabric that doesn't hold onto bacteria, and she's launched an activewear brand of men's and women's T-shirts that don't stink. But when the coronavirus hit the country and medical professionals worried about personal protection equipment, Eddings sprung into action.

"We have enough supplies here to make 9,000 masks and I have 2,800 yards of fabric sitting at my factory in California," she says. "That's enough fabric to make more than 100,000 masks." Click here to read more about Houston fashion designers looking to help out.

Lance Black, associate director of TMCx

Photo courtesy of TMCx

Telemedicine has a unique opportunity during the coronavirus-cased shutdown. Lance Black, associate director of the Texas Medical Center's accelerator, TMCx, joined the Houston Innovators Podcast to discuss the health tech potential as well as how startups are coping in this uncertain time.

"This is going to force the health care system to take a hard look at what these platforms are capable of doing," Black says in the episode. "And it's going to stress the capabilities of these companies. To be honest, if there's a silver lining, that is one of them in my mind, that this will prove out the technology [in telehealth.]" Click here to read more and stream the episode.

Todd Burke, president at Smith and Associates

Photo courtesy of Smith and Associates

The COVID-19 outbreak has already greatly affected supply chains across industries, and companies should keep moving forward with that in mind. Todd Burke, president at Houston-based Smith and Associates gives three tips for properly managing your supply chain during the coronavirus outbreak in a guest article.

"During my 23 years at Smith, the world's largest open-market distributor of electronic components, I've witnessed various market disruptions and shifting supply chain dynamics," writes Burke. "I can confidently say that the coronavirus outbreak is heavily uncharted territory for the technology industry." Click here to read more.

Coronavirus likely will affect your supply chain — here's what to keep in mind. Getty Images

Houston expert: Here are 3 tips for a resilient supply chain during the coronavirus outbreak

Guest column

Consumers rarely consider the intricacies of managing a cohesive supply chain when the process needed to deliver product to market is free of disruptors. In short, engineering and design work is completed, a bill of materials is established, material is sourced, and product is manufactured.

Manufacturers often expect to easily purchase product off the shelves or online. When external factors come into play that have the potential to disrupt supply chains and the quick availability of product, proper management is even more critical for businesses and their customers.

During my 23 years at Smith, the world's largest open-market distributor of electronic components, I've witnessed various market disruptions and shifting supply chain dynamics. I can confidently say that the coronavirus outbreak is heavily uncharted territory for the technology industry. Mitigating supply chain disruptions during troubling times, however, is familiar to us. Even through uncertainty, I want companies to know that there are many options to keep their supply chains active.

Here are my top three tips for properly managing your supply chain during the coronavirus outbreak:

Assess inventory levels and run outages scenarios

It is important to not only assess your on-hand inventory levels but to quickly gauge the impact and availability of product from key suppliers. As a precaution and to prevent further spread of the virus, many electronic component manufacturing plants in China were shut down for weeks, and some are still running at limited capacity with prominent labor shortages.

Finding out which manufacturers have been shut down or are affected by the virus will help determine lead times and availability requirements. Surveying suppliers is an efficient way to gauge manufacturers' levels of impact and determine your own needs. Bear in mind what possible logistics delays you may encounter when assessing your material levels.

Build contingency plans with alternative sources.

With supply constraints from traditional sources being almost an inevitability, having flexible sourcing options and relationships with key suppliers is a prime strategy for contingency planning.

On top of that, make sure your sourcing partner has put stringent quality procedures in place and is certified to the highest industry standards. Expanding your AVL (approved vendor list) and qualifying other manufacturers will help keep lines running according to forecast.

Ensuring heightened supplier screenings with end-to-end evaluation transparency is even more essential during times of disruption. Trusted, multichannel sourcing capabilities are prime options in the face of the consistently evolving global situation.

Stay vigilant, and work closely with your emergency response team.

Uncertainty will continue to play a major role throughout the outbreak situation. From my experience, staying up to date with the latest news and maintaining frequent communication with both internal and external parties is one of the most proactive approaches to disruptive situations.

Smith's shipping and logistics hubs have mirrored capabilities and are located in Houston, Hong Kong, and Amsterdam, so we have been able to keep our operations running throughout the outbreak. Although Smith's business operations have continued without any shutdowns, the electronics supply chain has been significantly impacted, and disruptions will be felt for some time. The effects of the coronavirus are expected to trickle down to end consumers, as new product introductions for some consumer electronics have been delayed. Reports are even indicating that the supply and availability of technology products during the peak holiday season may be disrupted.

With the millions of components that go into everything from consumer electronics to oil and gas and medical equipment, our industry could see notable shortages in supply throughout the year. I encourage all companies and especially our friends here in Houston to thoroughly evaluate their supply chains. Utilizing these tips to implement a resilient supply chain will help build a strategic business outlook.

------

Todd Burke is president at Houston-based Smith and Associates.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings